Genmab Target Price

Where could GMAB trade next? Consensus target price: $42.

Get informed when a big investor buys or sells

+ Follow

Share Price

$33.6

Average Target Price

$41.50

23.5% upside

2 analysts in the last 4 months

High: $43 | Low: $40

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-22	New Street	$43	28% upside
2026-05-27	Truist FinancialGregory Renza	$40	19% upside
2026-04-30	H.C. Wainwright	$38	13.1% upside
2026-03-26	Wolfe Research	$32	4.8% downside
2026-02-23	GuggenheimMichael Schmidt	$40	19% upside
2026-02-17	JefferiesBenjamin Jackson	$41.5	23.5% upside
2026-01-20	H.C. Wainwright	$39	16.1% upside
2025-11-06	Truist FinancialAsthika Goonewardene	$48	42.9% upside
2025-10-06	Truist FinancialAsthika Goonewardene	$49	45.8% upside
2025-10-02	H.C. Wainwright	$40	19% upside
2025-09-29	Leerink PartnersJonathan Chang	$34	1.2% upside
2025-09-23	GuggenheimMichael Schmidt	$43	28% upside
2025-03-11	Truist FinancialAsthika Goonewardene	$45	33.9% upside
2024-09-04	Morgan StanleyVikram Purohit	$31	7.7% downside
2024-08-09	BMO CapitalEtzer Darout	$46	36.9% upside
2024-06-27	BTIGKaveri Pohlman	$47	39.9% upside
2024-06-27	H.C. WainwrightRaghuram Selvaraju	$50	48.8% upside
2024-06-04	Truist FinancialAsthika Goonewardene	$53	57.7% upside
2024-02-23	BMO CapitalEtzer Darout	$48	42.9% upside
2023-02-06	Leerink Partners	$36	7.1% upside
2022-11-28	Morgan StanleyMatthew Harrison	$34	1.2% upside
2022-05-02	Cowen & Co.	$38	13.1% upside

Genmab (GMAB) FAQ

Genmab's target price stands at $42. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $42 for GMAB implies 23.5% upside versus today's price ($33.6). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Genmab's target price evolved across reporting periods, while the comparison chart places GMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Genmab's reading of $42 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.